Standout Papers

A One-Year Trial of Lamivudine for Chronic Hepatitis B 1998 2026 2007 2016 1.4k
  1. A One-Year Trial of Lamivudine for Chronic Hepatitis B (1998)
    Ching‐Lung Lai, Rong‐Nan Chien et al. New England Journal of Medicine
  2. Viral hepatitis B (2003)
    Ching‐Lung Lai, Vlad Ratziu et al. The Lancet
  3. Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B (2006)
    Ching‐Lung Lai, Daniel Shouval et al. New England Journal of Medicine
  4. Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B†,‡ (2010)
    Ting‐Tsung Chang, Yun‐Fan Liaw et al. Hepatology
  5. Viral hepatitis C (2003)
    Thierry Poynard, Man‐Fung Yuen et al. The Lancet
  6. Long-term safety of lamivudine treatment in patients with chronic hepatitis B (2003)
    Anna S. Lok, Ching‐Lung Lai et al. Gastroenterology
  7. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B (2000)
    Yun‐Fan Liaw, Nancy W.Y. Leung et al. Gastroenterology
  8. Telbivudine versus Lamivudine in Patients with Chronic Hepatitis B (2007)
    Ching‐Lung Lai, Edward Gane et al. New England Journal of Medicine
  9. Hepatitis B virus infection (2018)
    Man‐Fung Yuen, Ding‐Shinn Chen et al. Nature Reviews Disease Primers
  10. Entecavir Treatment for Up to 5 Years in Patients With Hepatitis B E Antigen–Positive Chronic Hepatitis B (2010)
    Ting‐Tsung Chang, Ching‐Lung Lai et al. Hepatology
  11. Epidemiology of Hepatocellular Carcinoma in the Asia-Pacific Region (2016)
    Ran Zhu, Wai‐Kay Seto et al. Gut and Liver

Immediate Impact

5 by Nobel laureates 5 from Science/Nature 145 standout
Sub-graph 1 of 15

Citing Papers

Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
2025 Standout
Hepatitis B
2023 Standout
52 intermediate papers

Works of Ching‐Lung Lai being referenced

RNA Interference Therapy With ARC‐520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection
2019
RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg
2017
and 70 more

Author Peers

Author Last Decade Papers Cites
Ching‐Lung Lai 27362 27083 3701 4179 572 35.3k
K. Rajender Reddy 24323 27667 5180 3834 577 36.3k
Anna S. Lok 39673 38461 3804 3653 553 46.8k
Jay H. Hoofnagle 29885 29585 4086 3797 388 42.8k
Thierry Poynard 35335 33163 4255 2807 425 42.7k
Thomas Berg 19785 19755 1885 3169 715 27.3k
Stefan Zeuzem 32059 33445 3983 4963 1.0k 45.8k
Ding‐Shinn Chen 28311 27144 2498 3125 751 37.8k
Zachary Goodman 32446 30336 4296 3333 293 40.9k
Adrian M. Di Bisceglie 23266 23261 2203 2129 380 32.6k
John G. McHutchison 32868 36416 1651 4593 459 42.6k

All Works

Loading papers...

Rankless by CCL
2026